XNAS 14 Oct, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Mr. Amir H. Shojaei | CHIEF SCIENTIFIC OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.96 per share. | 14 Aug 2026 | 11,250 | 11,250 (0%) | 0% | 36.0 | 404,550 | Common Stock |
| Mr. Amir H. Shojaei | CHIEF SCIENTIFIC OFFICER | 14 Aug 2026 | 11,250 | 18,750 | - | - | Stock Option (Right to Buy) | ||
| Mr. Amir H. Shojaei | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 14 Aug 2026 | 11,250 | 0 (0%) | 0% | 40 | 450,000 | Common Stock |
| Ms. Lauren P. Silvernail | Director | 18 Jun 2026 | 5,248 | 5,248 | - | - | RSU | ||
| Dr. Adrienne L. Graves,PhD | Director | 18 Jun 2026 | 5,248 | 5,248 | - | - | RSU | ||
| Mr. Perry J. Sternberg | Director | 18 Jun 2026 | 5,248 | 5,248 | - | - | RSU | ||
| Ms. Lauren P. Silvernail | Director | Purchase of securities on an exchange or from another person at price $ 31.00 per share. | 18 May 2026 | 1,000 | 1,000 (0%) | 0% | 31 | 31,000 | Common Stock |
| Dr. Adrienne L. Graves,PhD | Director | Purchase of securities on an exchange or from another person at price $ 31.07 per share. | 18 May 2026 | 1,000 | 1,000 (0%) | 0% | 31.1 | 31,070 | Common Stock |
| Mr. Amir H. Shojaei | CHIEF SCIENTIFIC OFFICER | 15 May 2026 | 10,000 | 10,000 | - | - | Restricted Stock Units | ||
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 30.20 per share. | 14 May 2026 | 10,000 | 2,996,130 (11%) | 0% | 30.2 | 302,000 | Common Stock |
| Mr. Andrew R. Boll | PRESIDENT AND CFO | Purchase of securities on an exchange or from another person at price $ 29.90 per share. | 14 May 2026 | 3,500 | 814,679 (3%) | 0% | 29.9 | 104,650 | Common Stock |
| Mr. Patrick William Sullivan | CHIEF COMMERCIAL OFFICER | 30 Jan 2026 | 25,000 | 25,000 | - | - | RSU | ||
| Mr. Patrick William Sullivan | CHIEF COMMERCIAL OFFICER | 30 Jan 2026 | 15,000 | 15,000 | - | - | RSU | ||
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. | 12 Dec 2025 | 180,000 | 3,066,124 (12%) | 0% | 4.0 | 711,000 | Common Stock |
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER | 12 Dec 2025 | 180,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.06 per share. | 12 Dec 2025 | 79,994 | 2,986,130 (11%) | 0% | 47.1 | 3,764,518 | Common Stock |
| Mr. Andrew R. Boll | PRESIDENT AND CFO | 12 Dec 2025 | 60,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Andrew R. Boll | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.06 per share. | 12 Dec 2025 | 26,665 | 811,179 (3%) | 0% | 47.1 | 1,254,855 | Common Stock |
| Mr. Andrew R. Boll | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. | 12 Dec 2025 | 60,000 | 837,844 (3%) | 0% | 4.0 | 237,000 | Common Stock |
| Mr. Randall E. Pollard | CHIEF ACCOUNTING OFFICER | 01 Sep 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER, Ten Percent Owner | 21 Jul 2025 | 600,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.87 per share. | 21 Jul 2025 | 600,000 | 3,199,462 (12%) | 2% | 7.9 | 4,722,000 | Common stock |
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.08 per share. | 21 Jul 2025 | 313,338 | 2,886,124 (11%) | 1% | 37.1 | 11,618,573 | Common stock |
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER | 01 Jul 2025 | 889,500 | 889,500 | - | - | RSU | ||
| Mr. Andrew R. Boll | CHIEF FINANCIAL OFFICER | 01 Jul 2025 | 405,750 | 405,750 | - | - | RSU | ||
| Ms. Lauren P. Silvernail | Director | 20 Jun 2025 | 7,339 | 7,339 | - | - | RSU | ||
| Dr. Adrienne L. Graves,PhD | Director | 20 Jun 2025 | 7,339 | 7,339 | - | - | RSU | ||
| Mr. Perry J. Sternberg | Director | 20 Jun 2025 | 7,339 | 7,339 | - | - | RSU | ||
| Mr. Mark L. Baum | Director, Chief Executive Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2025 | 762,300 | 2,899,825 (11%) | 3% | 0 | Common Stock | |
| Mr. Mark L. Baum | Director, Chief Executive Officer, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.09 per share. | 03 Apr 2025 | 300,363 | 2,599,462 (10%) | 1% | 23.1 | 6,935,382 | Common Stock |
| Mr. Mark L. Baum | Director, Chief Executive Officer, Ten Percent Owner | 03 Apr 2025 | 762,300 | 0 | - | - | Performance Stock Unit | ||
| Mr. John P. Saharek | CEO & President, ImprimisRx | 03 Apr 2025 | 277,200 | 0 | - | - | Performance Stock Unit | ||
| Mr. John P. Saharek | CEO & President, ImprimisRx | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2025 | 277,200 | 576,863 (2%) | 1% | 0 | Common Stock | |
| Mr. John P. Saharek | CEO & President, ImprimisRx | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.09 per share. | 03 Apr 2025 | 109,475 | 467,388 (1%) | 0% | 23.1 | 2,527,778 | Common Stock |
| Mr. Andrew R. Boll | Chief Financial Officer | 03 Apr 2025 | 346,500 | 0 | - | - | Performance Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2025 | 346,500 | 914,589 (3%) | 1% | 0 | Common Stock | |
| Mr. Andrew R. Boll | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.09 per share. | 03 Apr 2025 | 136,745 | 777,844 (3%) | 0% | 23.1 | 3,157,442 | Common Stock |
| Mr. Amir H. Shojaei | CHIEF SCIENTIFIC OFFICER | 06 Jan 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | ||
| John Saharek | CEO of ImprimisRx | 11 Sep 2024 | 90,000 | 344,803 (1%) | 0% | 7.4 | 663,300 | Common stock | |
| John Saharek | CEO of ImprimisRx | 11 Sep 2024 | 90,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| John Saharek | CEO of ImprimisRx | 11 Sep 2024 | 45,140 | 299,663 (1%) | 0% | 41.4 | 1,867,442 | Common stock | |
| Ms. Lauren P. Silvernail | Director | 14 Jun 2024 | 8,347 | 8,347 | - | - | RSU | ||
| Dr. Adrienne L. Graves,PhD | Director | 14 Jun 2024 | 8,347 | 8,347 | - | - | RSU | ||
| Mr. Perry J. Sternberg | Director | 14 Jun 2024 | 8,347 | 8,347 | - | - | RSU | ||
| Dr. Martin A. Makary, M.D. | Director | 14 Jun 2024 | 8,347 | 8,347 | - | - | RSU | ||
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER | Purchase of securities on an exchange or from another person at price $ 11.59 per share. | 22 Mar 2024 | 9,000 | 2,137,525 (8%) | 0% | 11.6 | 104,310 | Common stock |
| Mr. John Saharek | CEO of ImprimisRx | 01 Mar 2024 | 5,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. John Saharek | CEO of ImprimisRx | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.75 per share. | 01 Mar 2024 | 5,000 | 254,803 (1%) | 0% | 8.8 | 43,750 | Common stock |
| Mr. Andrew R. Boll | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.67 per share. | 20 Feb 2024 | 45,000 | 586,569 (2%) | 0% | 10.7 | 480,150 | Common stock |
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.67 per share. | 20 Feb 2024 | 59,836 | 2,128,525 (8%) | 0% | 10.7 | 638,450 | Common stock |
| Mr. John Saharek | CEO of ImprimisRx | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.67 per share. | 20 Feb 2024 | 30,000 | 262,419 (1%) | 0% | 10.7 | 320,100 | Common stock |
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER | 20 Feb 2024 | 150,000 | 0 | - | - | RSU | ||
| Mr. Andrew R. Boll | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.67 per share. | 20 Feb 2024 | 18,480 | 568,089 (2%) | 0% | 10.7 | 197,182 | Common stock |
| Mr. John Saharek | CEO of ImprimisRx | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.67 per share. | 20 Feb 2024 | 12,616 | 249,803 (0%) | 0% | 10.7 | 134,613 | Common stock |
| Mr. Andrew R. Boll | CHIEF FINANCIAL OFFICER | 20 Feb 2024 | 45,000 | 0 | - | - | RSU | ||
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.67 per share. | 20 Feb 2024 | 150,000 | 2,188,361 (8%) | 0% | 10.7 | 1,600,500 | Common stock |
| Mr. John Saharek | CEO of ImprimisRx | 20 Feb 2024 | 30,000 | 0 | - | - | RSU | ||
| Mr. Andrew R. Boll | CHIEF FINANCIAL OFFICER | 07 Feb 2024 | 7,400 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER | 07 Feb 2024 | 15,400 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Andrew R. Boll | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.71 per share. | 07 Feb 2024 | 7,400 | 541,569 (2%) | 0% | 7.7 | 57,054 | Common stock |
| Mr. Mark L. Baum | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.71 per share. | 07 Feb 2024 | 15,400 | 2,038,361 (8%) | 0% | 7.7 | 118,734 | Common stock |
| Ms. Lauren P. Silvernail | Director | 26 Jan 2024 | 3,119 | 3,119 | - | - | RSU | ||
| Dr. Adrienne L. Graves,PhD | Director | 26 Jan 2024 | 3,119 | 3,119 | - | - | RSU | ||
| Mr. Mark L. Baum | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 8.11 per share. | 16 Nov 2023 | 7,500 | 2,022,961 (8%) | 0% | 8.1 | 60,825 | - |
| Mr. John Saharek | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.83 per share. | 10 Nov 2023 | 9,778 | 232,419 (0%) | 0% | 12.8 | 125,452 | - |
| Mr. John Saharek | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2023 | 20,000 | 242,197 (0%) | 0% | - | - | |
| Mr. Mark L. Baum | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 17.05 per share. | 14 Aug 2023 | 5,800 | 2,015,461 (8%) | 0% | 17.1 | 98,890 | Common Stock |
| Dr. Martin A. Makary, M.D. | Director | Purchase of securities on an exchange or from another person at price $ 16.92 per share. | 14 Aug 2023 | 20,000 | 45,000 (0%) | 0% | 16.9 | 338,400 | Common Stock |
| Mr. Mark L. Baum | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2023 | 762,300 | 2,309,629 (9%) | 3% | - | Common Stock | |
| Mr. Mark L. Baum | Director, Chief Executive Officer | 18 Jul 2023 | 762,300 | 0 | - | - | Performance Stock Unit | ||
| Mr. Mark L. Baum | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.23 per share. | 18 Jul 2023 | 299,968 | 2,009,661 (7%) | 1% | 18.2 | 5,468,417 | Common Stock |
| Mr. John Saharek | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.23 per share. | 18 Jul 2023 | 109,080 | 222,197 (0%) | 0% | 18.2 | 1,988,528 | Common Stock |
| Mr. John Saharek | Chief Commercial Officer | 18 Jul 2023 | 277,200 | 0 | - | - | Performance Stock Unit | ||
| Mr. John Saharek | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2023 | 277,200 | 331,277 (1%) | 1% | - | Common Stock | |
| Mr. Andrew R. Boll | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.23 per share. | 18 Jul 2023 | 136,350 | 534,169 (2%) | 0% | 18.2 | 2,485,661 | Common Stock |
| Mr. Andrew R. Boll | Chief Financial Officer | 18 Jul 2023 | 346,500 | 0 | - | - | Performance Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2023 | 346,500 | 670,519 (2%) | 1% | - | Common Stock | |
| Professor R. Lawrence Van Horn, PhD | Director | 21 Jun 2023 | 7,744 | 7,744 | - | - | RSU | ||
| Ms. Teresa F. Sparks | Director | 21 Jun 2023 | 7,744 | 7,744 | - | - | RSU | ||
| Mr. Perry J. Sternberg | Director | 21 Jun 2023 | 7,744 | 7,744 | - | - | RSU | ||
| Dr. Martin A. Makary, M.D. | Director | 21 Jun 2023 | 7,744 | 7,744 | - | - | RSU | ||
| Mr. Mark L. Baum | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.97 per share. | 03 Apr 2023 | 117,633 | 1,547,329 (6%) | 0% | 21.0 | 2,466,764 | Common Stock |
| Mr. Mark L. Baum | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.99 per share. | 03 Apr 2023 | 180,000 | 1,664,962 (6%) | 0% | 9.0 | 1,618,200 | Common Stock |
| Mr. Mark L. Baum | Director, Chief Executive Officer | 03 Apr 2023 | 180,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Mark L. Baum | Director, Chief Executive Officer | 03 Apr 2023 | 762,300 | 762,300 | - | - | Restricted Stock Unit | ||
| Mr. John Saharek | Chief Commercial Officer | 03 Apr 2023 | 277,200 | 277,200 | - | - | Restricted Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 31 Mar 2023 | 346,500 | 346,500 | - | - | Restricted Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 31 Mar 2023 | 90,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Andrew R. Boll | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 31 Mar 2023 | 34,442 | 324,019 (1%) | 0% | 21.2 | 728,793 | Common Stock |
| Mr. Andrew R. Boll | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.00 per share. | 31 Mar 2023 | 90,000 | 358,461 (1%) | 0% | 6 | 540,000 | Common Stock |
| Mr. Mark L. Baum | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.76 per share. | 02 Jan 2023 | 35,179 | 1,484,962 (5%) | 0% | 14.8 | 519,242 | Common Stock |
| Mr. Mark L. Baum | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2023 | 88,000 | 1,520,141 (6%) | 0% | - | Common Stock | |
| Mr. Mark L. Baum | Director, Chief Executive Officer | 02 Jan 2023 | 88,000 | 0 | - | - | Restricted Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 02 Jan 2023 | 23,000 | 0 | - | - | Restricted Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.76 per share. | 02 Jan 2023 | 9,602 | 268,461 (1%) | 0% | 14.8 | 141,726 | Common Stock |
| Mr. Andrew R. Boll | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2023 | 23,000 | 278,063 (1%) | 0% | - | Common Stock | |
| Mr. Mark L. Baum | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 13.39 per share. | 22 Dec 2022 | 25,000 | 1,432,141 (5%) | 0% | 13.4 | 334,750 | Common Stock |
| Mr. Andrew R. Boll | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 13.54 per share. | 22 Dec 2022 | 2,500 | 255,063 (1%) | 0% | 13.5 | 33,850 | Common Stock |
| Professor R. Lawrence Van Horn, PhD | Director | Purchase of securities on an exchange or from another person at price $ 13.42 per share. | 22 Dec 2022 | 1,860 | 1,860 (0%) | 0% | 13.4 | 24,961 | Common Stock |
| Dr. Martin A. Makary, M.D. | Director | Purchase of securities on an exchange or from another person at price $ 13.37 per share. | 21 Dec 2022 | 25,000 | 25,000 (0%) | 0% | 13.4 | 334,250 | Common Stock |
| Dr. Richard L. Lindstrom,M.D. | Director | Sale of securities on an exchange or to another person at price $ 12.62 per share. | 30 Sep 2022 | 40,000 | 26,100 (0%) | 0% | 12.6 | 504,800 | Common Stock |
| Dr. Richard L. Lindstrom,M.D. | Director | 09 Jun 2022 | 13,123 | 13,123 | - | - | RSU | ||
| Professor R. Lawrence Van Horn, PhD | Director | 09 Jun 2022 | 13,123 | 13,123 | - | - | RSU | ||
| Ms. Teresa F. Sparks | Director | 09 Jun 2022 | 13,123 | 13,123 | - | - | RSU | ||
| Mr. Perry J. Sternberg | Director | 09 Jun 2022 | 13,123 | 13,123 | - | - | RSU | ||
| Dr. Martin A. Makary, M.D. | Director | 09 Jun 2022 | 13,123 | 13,123 | - | - | RSU | ||
| Mr. John Saharek | President, ImprimisRx | 19 Feb 2022 | 50,000 | 0 | - | - | Restricted Stock Unit | ||
| Mr. John Saharek | President, ImprimisRx | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.87 per share. | 19 Feb 2022 | 25,923 | 54,077 (0%) | 0% | 7.9 | 204,014 | Common Stock |
| Mr. John Saharek | President, ImprimisRx | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2022 | 50,000 | 80,000 (0%) | 0% | - | Common Stock | |
| Mr. Andrew R. Boll | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.87 per share. | 19 Feb 2022 | 20,605 | 252,563 (1%) | 0% | 7.9 | 162,161 | Common Stock |
| Mr. Andrew R. Boll | Chief Financial Officer | 19 Feb 2022 | 50,000 | 0 | - | - | Restricted Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2022 | 50,000 | 273,168 (1%) | 0% | - | Common Stock | |
| Mr. Mark L. Baum | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.40 per share. | 20 Jan 2022 | 125,000 | 1,478,547 (5%) | 0% | 2.4 | 300,000 | - |
| Mr. Mark L. Baum | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.33 per share. | 20 Jan 2022 | 71,406 | 1,407,141 (5%) | 0% | 8.3 | 594,812 | - |
| Dr. Richard L. Lindstrom,M.D. | Director | Sale of securities on an exchange or to another person at price $ 10.04 per share. | 24 Sep 2021 | 3,900 | 66,100 (0%) | 0% | 10.0 | 39,156 | Common Stock |
| Dr. Richard L. Lindstrom,M.D. | Director | Sale of securities on an exchange or to another person at price $ 9.02 per share. | 15 Sep 2021 | 5,840 | 70,000 (0%) | 0% | 9.0 | 52,677 | Common Stock |
| Dr. Richard L. Lindstrom,M.D. | Director | Sale of securities on an exchange or to another person at price $ 9.09 per share. | 15 Sep 2021 | 14,160 | 75,840 (0%) | 0% | 9.1 | 128,714 | Common Stock |
| Mr. Mark L. Baum | Director, Chief Executive Officer | 23 Jul 2021 | 762,301 | 762,301 | - | - | Restricted Stock Unit | ||
| Mr. John Saharek | President, ImprimisRx | 23 Jul 2021 | 277,200 | 277,200 | - | - | Restricted Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 23 Jul 2021 | 346,500 | 346,500 | - | - | Restricted Stock Unit | ||
| Dr. Richard L. Lindstrom,M.D. | Director | 25 Jun 2021 | 9,644 | 9,644 | - | - | RSU | ||
| Dr. Robert J. Kammer | Director | 25 Jun 2021 | 9,644 | 9,644 | - | - | RSU | ||
| Mr. R. Lawrence Van Horn, PhD | Director | 25 Jun 2021 | 9,644 | 9,644 | - | - | RSU | ||
| Ms. Teresa F. Sparks | Director | 25 Jun 2021 | 9,644 | 9,644 | - | - | RSU | ||
| Dr. Richard L. Lindstrom,M.D. | Director | Sale of securities on an exchange or to another person at price $ 10.75 per share. | 20 May 2021 | 10,000 | 90,000 (0%) | 0% | 10.8 | 107,500 | Common Stock |
| Mr. Mark L. Baum | Director, Chief Executive Officer | 25 Apr 2021 | 850,000 | 0 | - | - | Restricked Stock Unit | ||
| Mr. Mark L. Baum | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.26 per share. | 25 Apr 2021 | 334,129 | 1,353,547 (5%) | 1% | 8.3 | 2,759,906 | Common Stock |
| Mr. Mark L. Baum | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2021 | 850,000 | 1,687,676 (6%) | 3% | 0 | Common Stock | |
| Mr. Andrew R. Boll | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2021 | 127,500 | 273,000 (1%) | 0% | 0 | Common Stock | |
| Mr. Andrew R. Boll | Chief Financial Officer | 25 Apr 2021 | 127,500 | 0 | - | - | Restricked Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.26 per share. | 25 Apr 2021 | 49,832 | 223,168 (0%) | 0% | 8.3 | 411,612 | Common Stock |
| Mr. Mark L. Baum | Director, Chief Executive Officer | 25 Feb 2021 | 200,000 | 850,000 | - | - | Restricted Stock Unit | ||
| Mr. Mark L. Baum | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 200,000 | 837,676 (3%) | 0% | - | Common Stock | |
| Mr. Andrew R. Boll | Chief Financial Officer | 25 Feb 2021 | 30,000 | 127,500 | - | - | Restricted Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.68 per share. | 25 Feb 2021 | 7,500 | 145,500 (0%) | 0% | 7.7 | 57,600 | Common Stock |
| Mr. Andrew R. Boll | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 30,000 | 153,000 (0%) | 0% | - | Common Stock | |
| Mr. Mark L. Baum | Director, Chief Executive Officer | 19 Feb 2021 | 150,000 | 150,000 | - | - | Restricted Stock Unit | ||
| Mr. John Saharek | President, ImprimisRx | 19 Feb 2021 | 30,000 | 30,000 | - | - | Restricted Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 19 Feb 2021 | 45,000 | 45,000 | - | - | Restricted Stock Unit | ||
| Mr. Anthony J. Principi | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Sep 2020 | 93,798 | 93,798 (0%) | 0% | 0 | COMMON STOCK | |
| Mr. Anthony J. Principi | Director | 28 Sep 2020 | 4,573 | 93,798 | - | - | RSU | ||
| Mr. Anthony J. Principi | Director | 28 Sep 2020 | 12,690 | 89,225 | - | - | RSU | ||
| Mr. Anthony J. Principi | Director | 28 Sep 2020 | 15,723 | 76,535 | - | - | RSU | ||
| Mr. Anthony J. Principi | Director | 28 Sep 2020 | 34,091 | 60,812 | - | - | RSU | ||
| Mr. Anthony J. Principi | Director | 28 Sep 2020 | 9,715 | 26,721 | - | - | RSU | ||
| Mr. Anthony J. Principi | Director | 28 Sep 2020 | 17,006 | 17,006 | - | - | RSU | ||
| Mr. R. Lawrence Van Horn, PhD | Director | 28 Sep 2020 | 12,500 | 12,500 | - | - | RSU | ||
| Mr. Anthony J. Principi | Director | 04 Jun 2020 | 17,006 | 17,006 | - | - | RSU | ||
| Mr. Mark L. Baum | Director, Chief Executive Officer | 04 Jun 2020 | 600,000 | 0 | - | - | Employee Stock Option - Right to Buy | ||
| Mr. Mark L. Baum | Director, Chief Executive Officer | 04 Jun 2020 | 600,000 | 600,000 | - | - | Employee Stock Option - Right to Buy | ||
| Dr. Richard L. Lindstrom,M.D. | Director | 04 Jun 2020 | 17,006 | 17,006 | - | - | RSU | ||
| Dr. Robert J. Kammer | Director | 04 Jun 2020 | 17,006 | 17,006 | - | - | RSU | ||
| Ms. Teresa F. Sparks | Director | 04 Jun 2020 | 17,006 | 17,006 | - | - | RSU | ||
| Mr. Stephen G. Austin, C.P.A. | Director | 16 Mar 2020 | 9,715 | 0 | - | - | RSU | ||
| Mr. Stephen G. Austin, C.P.A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2020 | 72,218 | 91,987 (0%) | - | 0 | COMMON STOCK | |
| Mr. Stephen G. Austin, C.P.A. | Director | 16 Mar 2020 | 12,690 | 59,529 | - | - | RSU | ||
| Mr. Stephen G. Austin, C.P.A. | Director | 16 Mar 2020 | 15,723 | 43,806 | - | - | RSU | ||
| Mr. Stephen G. Austin, C.P.A. | Director | 16 Mar 2020 | 34,091 | 9,715 | - | - | RSU | ||
| Ms. Teresa F. Sparks | Director | 16 Mar 2020 | 10,000 | 10,000 | - | - | RSU | ||
| Mr. Mark L. Baum | Director, Chief Executive Officer | 02 Jan 2020 | 88,000 | 88,000 | - | - | Restricted Stock Unit | ||
| Mr. Mark L. Baum | Director, Chief Executive Officer | 02 Jan 2020 | 217,500 | 217,500 | - | - | Option - Right to Buy | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 02 Jan 2020 | 23,000 | 23,000 | - | - | Restricted Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 02 Jan 2020 | 57,000 | 57,000 | - | - | Option - Right to Buy | ||
| Mark L. Baum | Director, Chief Executive Officer | 22 Nov 2019 | 156,000 | 0 | - | - | Purchase Warrant | ||
| Mark L. Baum | Director, Chief Executive Officer | 22 Nov 2019 | 156,000 | 598,126 (2%) | 0% | 1.8 | 279,240 | Common Stock | |
| Mr. Andrew R. Boll | Chief Financial Officer | 22 Nov 2019 | 39,000 | 123,000 (0%) | 0% | 1.8 | 69,810 | Common Stock | |
| Mr. Andrew R. Boll | Chief Financial Officer | 22 Nov 2019 | 39,000 | 0 | - | - | Purchase Warrant | ||
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 11 Nov 2019 | 6,500 | 797,327 (3%) | 0% | 4.8 | 30,875 | Common Stock |
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 5.25 per share. | 07 Oct 2019 | 6,500 | 803,827 (3%) | 0% | 5.3 | 34,125 | Common Stock |
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 5.67 per share. | 09 Sep 2019 | 6,500 | 810,327 (3%) | 0% | 5.7 | 36,855 | Common Stock |
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 6.89 per share. | 12 Aug 2019 | 6,500 | 816,827 (3%) | 0% | 6.9 | 44,785 | Common Stock |
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 7.91 per share. | 15 Jul 2019 | 6,500 | 823,327 (3%) | 0% | 7.9 | 51,415 | Common Stock |
| Anthony J. Principi | None | 26 Jun 2019 | 9,715 | 9,715 | - | - | RSU | ||
| Mr. Stephen G. Austin, C.P.A. | None | 26 Jun 2019 | 9,715 | 9,715 | - | - | RSU | ||
| Dr. Richard L. Lindstrom,M.D. | None | 26 Jun 2019 | 9,715 | 9,715 | - | - | RSU | ||
| Dr. Robert J. Kammer | None | 26 Jun 2019 | 9,715 | 9,715 | - | - | RSU | ||
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 5.78 per share. | 03 Jun 2019 | 10,000 | 829,827 (3%) | 0% | 5.8 | 57,800 | Common Stock |
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 4.57 per share. | 01 May 2019 | 10,000 | 839,827 (3%) | 0% | 4.6 | 45,700 | Common Stock |
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 4.77 per share. | 01 Apr 2019 | 10,000 | 849,827 (3%) | 0% | 4.8 | 47,700 | Common Stock |
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 6.91 per share. | 01 Mar 2019 | 10,000 | 859,827 (3%) | 0% | 6.9 | 69,100 | Common Stock |
| Mark L. Baum | Director, Chief Executive Officer | 19 Feb 2019 | 150,000 | 150,000 | - | - | Option - Right to Buy | ||
| Mr. John Saharek | Chief Commercial Officer | 19 Feb 2019 | 50,000 | 50,000 | - | - | Restricted Stock Unit | ||
| Mr. John Saharek | Chief Commercial Officer | 19 Feb 2019 | 50,000 | 50,000 | - | - | Option - Right to Buy | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 19 Feb 2019 | 50,000 | 50,000 | - | - | Restricted Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 19 Feb 2019 | 50,000 | 50,000 | - | - | Option - Right to Buy | ||
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 5.86 per share. | 01 Feb 2019 | 10,000 | 869,827 (3%) | 0% | 5.9 | 58,600 | Common Stock |
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 5.33 per share. | 02 Jan 2019 | 10,000 | 879,827 (3%) | 0% | 5.3 | 53,300 | Common Stock |
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 4.64 per share. | 03 Dec 2018 | 10,000 | 889,827 (3%) | 0% | 4.6 | 46,400 | Common Stock |
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 4.21 per share. | 01 Nov 2018 | 10,000 | 899,827 (3%) | 0% | 4.2 | 42,100 | Common Stock |
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 3.00 per share. | 15 Oct 2018 | 10,000 | 909,827 (4%) | 0% | 3 | 30,000 | Common Stock |
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 3.00 per share. | 04 Sep 2018 | 10,000 | 919,827 (4%) | 0% | 3 | 30,000 | Common Stock |
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 3.00 per share. | 10 Aug 2018 | 130,000 | 929,827 (4%) | 0% | 3 | 390,000 | Common Stock |
| Anthony J. Principi | None | 29 Jun 2018 | 34,091 | 34,091 | - | - | RSU | ||
| Mr. Stephen G. Austin, C.P.A. | None | 29 Jun 2018 | 34,091 | 34,091 | - | - | RSU | ||
| Dr. Richard L. Lindstrom,M.D. | None | 29 Jun 2018 | 34,091 | 34,091 | - | - | RSU | ||
| Dr. Robert J. Kammer | None | 29 Jun 2018 | 34,091 | 34,091 | - | - | RSU | ||
| Mr. John Saharek | Chief Commercial Officer | 01 Feb 2018 | 30,000 | 30,000 | - | - | Restricted Stock Unit | ||
| Mr. John Saharek | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.83 per share. | 01 Feb 2018 | 30,000 | 30,000 (0%) | 0% | 1.8 | 54,900 | Common Stock |
| Mr. Andrew R. Boll | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.83 per share. | 01 Feb 2018 | 30,000 | 84,000 (0%) | 0% | 1.8 | 54,900 | Common Stock |
| Mr. Andrew R. Boll | Chief Financial Officer | 01 Feb 2018 | 30,000 | 30,000 | - | - | Restricted Stock Unit | ||
| Mark L. Baum | Director, Chief Executive Officer | 02 Jan 2018 | 150,000 | 150,000 | - | - | Option - Right to Buy | ||
| Mr. John Saharek | Chief Commercial Officer | 02 Jan 2018 | 50,000 | 50,000 | - | - | Option - Right to Buy | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 02 Jan 2018 | 50,000 | 50,000 | - | - | Option - Right to Buy | ||
| Dr. Robert J. Kammer | None | Sale of securities on an exchange or to another person at price $ 3.05 per share. | 17 Jul 2017 | 10,000 | 1,059,827 (5%) | 0% | 3.1 | 30,526 | Common Stock |
| Anthony J. Principi | None | 13 Jun 2017 | 15,723 | 15,723 | - | - | RSU | ||
| Mr. Stephen G. Austin, C.P.A. | None | 13 Jun 2017 | 15,723 | 15,723 | - | - | RSU | ||
| Dr. Richard L. Lindstrom,M.D. | None | 13 Jun 2017 | 15,723 | 15,723 | - | - | RSU | ||
| Dr. Robert J. Kammer | None | 13 Jun 2017 | 15,723 | 15,723 | - | - | RSU | ||
| Dr. Richard L. Lindstrom,M.D. | None | 27 Apr 2017 | 100,000 | 0 | - | - | Purchase Warrant | ||
| Dr. Richard L. Lindstrom,M.D. | None | 27 Apr 2017 | 100,000 | 100,000 | - | - | Purchase Warrant | ||
| Dr. Richard L. Lindstrom,M.D. | None | 27 Apr 2017 | 100,000 | 0 | - | - | Purchase Warrant | ||
| Dr. Richard L. Lindstrom,M.D. | None | 27 Apr 2017 | 100,000 | 100,000 (0%) | 0% | 1.8 | 179,000 | Common Stock | |
| Mr. Clayton D Edwards | Chief Operating Officer | 13 Apr 2017 | 55,000 | 55,000 | - | - | Option - Right to Buy | ||
| Dr. Robert J. Kammer | None | Other type of transaction at price $ 0.00 per share. | 09 Mar 2017 | 20,000 | 1,069,827 (5%) | 0% | 0 | Common Stock | |
| Mark L. Baum | Director, Chief Executive Officer | 01 Feb 2017 | 160,000 | 160,000 | - | - | Option - Right to Buy | ||
| Mr. John Saharek | Chief Commercial Officer | 01 Feb 2017 | 55,000 | 55,000 | - | - | Option - Right to Buy | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 01 Feb 2017 | 55,000 | 55,000 | - | - | Option - Right to Buy | ||
| Dr. Richard L. Lindstrom,M.D. | None | 19 Dec 2016 | 100,000 | 100,000 | - | - | Purchase Warrant | ||
| Dr. Richard L. Lindstrom,M.D. | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Dec 2016 | 100,000 | 100,000 | - | - | Common Stock | |
| Mark L. Baum | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2016 | 200,000 | 525,835 | - | - | Common Stock | |
| Mark L. Baum | Director, Chief Executive Officer | 19 Dec 2016 | 156,000 | 156,000 | - | - | Purchase Warrant | ||
| Mark L. Baum | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Dec 2016 | 83,709 | 442,126 | - | - | Common Stock | |
| Mark L. Baum | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Dec 2016 | 156,000 | 325,835 | - | - | Common Stock | |
| Mark L. Baum | Director, Chief Executive Officer | 19 Dec 2016 | 200,000 | 0 | - | - | Restricted Stock Unit | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 19 Dec 2016 | 39,000 | 39,000 | - | - | Purchase Warrant | ||
| Mr. Andrew R. Boll | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Dec 2016 | 39,000 | 54,000 | - | - | Common Stock | |
| Dr. Robert J. Kammer | None | Other type of transaction at price $ 0.00 per share. | 02 Nov 2016 | 95,000 | 1,089,827 | - | - | Common Stock | |
| Stephen G. Austin,C.P.A. | None | 10 Jun 2016 | 12,690 | 12,690 | - | - | RSU | ||
| Dr. Richard L. Lindstrom,M.D. | None | 10 Jun 2016 | 12,690 | 12,690 | - | - | RSU | ||
| Anthony J. Principi | None | 10 Jun 2016 | 12,690 | 12,690 | - | - | RSU | ||
| Dr. Robert J. Kammer | None | 10 Jun 2016 | 12,690 | 12,690 | - | - | RSU | ||
| Mr. William H. Nelson, Jr | None | 10 Jun 2016 | 12,690 | 12,690 | - | - | RSU | ||
| Mark L. Baum | Director, Chief Executive Officer | 25 Apr 2016 | 1,050,000 | 0 | - | - | Executive RSU | ||
| Mark L. Baum | Director, Chief Executive Officer | 25 Apr 2016 | 1,050,000 | 1,050,000 | - | - | Executive RSU | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 25 Apr 2016 | 157,500 | 0 | - | - | Executive RSU | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 25 Apr 2016 | 157,500 | 157,500 | - | - | Executive RSU | ||
| Mark L. Baum | Director, Chief Executive Officer | 01 Apr 2016 | 180,000 | 180,000 | - | - | Option - Right to Buy | ||
| Mr. John Saharek | Chief Commercial Officer | 01 Apr 2016 | 60,000 | 60,000 | - | - | Option - Right to Buy | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 01 Apr 2016 | 60,000 | 60,000 | - | - | Option - Right to Buy | ||
| Mr. Andrew R. Boll | Chief Financial Officer | 01 Feb 2016 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Mr. Andrew R. Boll | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2016 | 15,000 | 202,500 | - | - | Common Stock | |
| Anthony J. Principi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2015 | 4,573 | 4,573 | - | - | Common Stock | |
| Dr. Richard L. Lindstrom,M.D. | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2015 | 4,469 | 10,750 | - | - | Common Stock | |
| Mark L. Baum | Director, Chief Executive Officer | 31 Jul 2015 | 600,000 | 600,000 | - | - | Employee Stock Option - Right to Buy | ||
| Stephen G. Austin,C.P.A. | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2015 | 6,281 | 19,769 | - | - | Common Stock | |
| Dr. Richard L. Lindstrom,M.D. | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2015 | 6,281 | 6,281 | - | - | Common Stock | |
| Dr. Robert J. Kammer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2015 | 6,281 | 994,827 | - | - | Common Stock | |
| Mr. William H. Nelson, Jr | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2015 | 6,281 | 12,904 | - | - | Common Stock | |
| Dr. Robert J. Kammer | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Apr 2015 | 15,282 | 988,546 | - | - | Common Stock | |
| Dr. Robert J. Kammer | Director, Ten Percent Owner | 23 Apr 2015 | 15,282 | 0 | - | - | Warrant (Right to Buy) | ||
| Mr. John Saharek | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2015 | 30,000 | 30,000 | - | - | Common Stock | |
| Mr. John Saharek | Chief Commercial Officer | 01 Feb 2015 | 90,000 | 90,000 | - | - | Option - Right to Buy | ||
| Mr. Andrew R. Boll | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2015 | 30,000 | 187,500 | - | - | Common Stock | |
| Mr. Andrew R. Boll | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2015 | 157,500 | 157,500 | - | - | Common Stock | |
| Dr. Robert J. Kammer | Director, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 30 Sep 2014 | 15,162 | 954,817 | - | - | Common Stock | |
| Dr. Robert J. Kammer | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2014 | 46,875 | 1,001,692 | - | - | Common Stock | |
| Dr. Robert J. Kammer | Director, Ten Percent Owner | 30 Sep 2014 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Dr. Robert J. Kammer | Director, Ten Percent Owner | 30 Sep 2014 | 46,875 | 0 | - | - | Stock Option (Right to Buy) | ||
| Dr. Robert J. Kammer | Director, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 30 Sep 2014 | 28,428 | 973,264 | - | - | Common Stock | |
| Dr. Robert J. Kammer | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2014 | 25,000 | 969,979 | - | - | Common Stock | |
| Stephen G. Austin,C.P.A. | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2014 | 6,623 | 13,488 | - | - | Common Stock | |
| Dr. Robert J. Kammer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2014 | 6,623 | 944,979 | - | - | Common Stock | |
| Mr. August S. Bassani | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2014 | 6,623 | 13,488 | - | - | Common Stock | |
| Mr. William H. Nelson, Jr | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2014 | 6,623 | 6,623 | - | - | Common Stock | |
| Mark L. Baum | Director, Chief Executive Officer | 10 Feb 2014 | 15,400 | 15,400 | - | - | Option - Right to Buy | ||
| Mr. Andrew R. Boll | VP, Accounting and Reporting | 10 Feb 2014 | 7,400 | 7,400 | - | - | Option - Right to Buy | ||
| Dr. Robert J. Kammer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2013 | 6,667 | 938,356 | - | - | Common Stock | |
| Mr. Peter Kenny | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2013 | 8,947 | 8,947 | - | - | Common Stock | |
| Dr. Paul W. Finnegan,M.D. | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2013 | 6,865 | 6,865 | - | - | COMMON STOCK | |
| Stephen G. Austin,C.P.A. | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2013 | 6,865 | 6,865 | - | - | COMMON STOCK | |
| Dr. Jeffrey J. Abrams,M.D. | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2013 | 6,865 | 45,927 | - | - | COMMON STOCK | |
| Dr. Robert J. Kammer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2013 | 6,865 | 898,356 | - | - | COMMON STOCK | |
| Dr. Robert J. Kammer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2013 | 33,333 | 931,689 | - | - | COMMON STOCK | |
| Mr. August S. Bassani | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2013 | 6,865 | 6,865 | - | - | COMMON STOCK | |
| Mark L. Baum | Director, Chief Executive Officer | 02 May 2013 | 180,000 | 180,000 | - | - | Option - Right to Buy | ||
| Mark L. Baum | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2013 | 1,050,000 | 1,219,835 | - | - | Common Stock | |
| Mark L. Baum | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2013 | 200,000 | 1,419,835 | - | - | Common Stock | |
| Dr. Joachim P.H. Schupp,M.D. | CHIEF MEDICAL OFFICER | 01 Apr 2013 | 25,000 | 25,000 | - | - | OPTION RIGHT TO BUY | ||
| Mr. Andrew R. Boll | VP ACCOUNTING AND REPORTING | 01 Apr 2013 | 90,000 | 90,000 | - | - | OPTION RIGHT TO BUY | ||
| Dr. Paul W. Finnegan,M.D. | None | 31 Dec 2012 | 125,000 | 150,000 | - | - | Option (Right to Buy) | ||
| Dr. Paul W. Finnegan,M.D. | None | 31 Dec 2012 | 25,000 | 150,000 | - | - | Option (Right to Buy) | ||
| Mark L. Baum | Director, Chief Executive Officer | 31 Dec 2012 | 856,087 | 0 | - | - | Convertible Debenture | ||
| Mark L. Baum | Director, Chief Executive Officer | 31 Dec 2012 | 856,087 | 0 | - | - | Convertible Debenture | ||
| Mark L. Baum | Director, Chief Executive Officer | 31 Dec 2012 | 125,000 | 125,000 | - | - | Option (Right to Buy) | ||
| Mark L. Baum | Director, Chief Executive Officer | 31 Dec 2012 | 60,000 | 60,000 | - | - | Option (Right to Buy) | ||
| Mark L. Baum | Director, Chief Executive Officer | 31 Dec 2012 | 25,000 | 25,000 | - | - | Option (Right to Buy) | ||
| Mark L. Baum | Director, Chief Executive Officer | 31 Dec 2012 | 48,262 | 0 | - | - | Warrants | ||
| Mark L. Baum | Director, Chief Executive Officer | 31 Dec 2012 | 2,413 | 2,413 | - | - | Warrants | ||
| Mark L. Baum | Director, Chief Executive Officer | 31 Dec 2012 | 1,454,962 | 0 | - | - | Common Stock | ||
| Mark L. Baum | Director, Chief Executive Officer | 31 Dec 2012 | 193,047 | 0 | - | - | Common Stock | ||
| Dr. Joachim P.H. Schupp,M.D. | Chief Medical Officer | 31 Dec 2012 | 493 | 75,493 | - | - | Employee Stock Option (Right to Buy) | ||
| Dr. Joachim P.H. Schupp,M.D. | Chief Medical Officer | 31 Dec 2012 | 75,000 | 75,493 | - | - | Employee Stock Option (Right to Buy) | ||
| Dr. Balbir Brar,D.V.M.,PhD | None | 31 Dec 2012 | 225,000 | 225,000 | - | - | Option (Right to Buy) | ||
| Dr. Balbir Brar,D.V.M.,PhD | None | 31 Dec 2012 | 25,000 | 25,000 | - | - | Option (Right to Buy) | ||
| Dr. John N. Bonfiglio, PhD | Director, President and CEO | 20 Oct 2010 | 400,000 | 400,000 | - | - | Stock option (right to buy) | ||
| Dr. John N. Bonfiglio, PhD | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Oct 2010 | 50,000 | 50,000 | - | - | Restricted Common Stock | |
| Terry M. Nida | Chief Business Officer | 26 Feb 2010 | 300,000 | 300,000 | - | - | Employee Stock Option (right to buy) | ||
| Dr. Joachim P.H. Schupp,M.D. | Chief Medical Officer | 14 Oct 2009 | 215,000 | 215,000 | - | - | Employee Stock Option (Right to Buy) | ||
| Dr. Juliet Singh,PhD | Director, CEO, Director and President, Ten Percent Owner | 18 Jun 2009 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | ||
| John T. Lomoro | Chief Financial Officer | 18 Jun 2009 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | ||
| Anthony S. Thornley | None | 21 Nov 2008 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | ||
| Mr. Lynn C. Swann | None | 21 Nov 2008 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Lynn C. Swann | None | 21 Nov 2008 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | ||
| Mr. Lynn C. Swann | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2008 | 25,000 | 25,000 | - | - | Common Stock, par value $0.001 per share | |
| Dr. Jeffrey J. Abrams,M.D. | Director, Ten Percent Owner | 21 Nov 2008 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | ||
| Dr. Juliet Singh,PhD | Director, CEO, Director and President, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 26 Sep 2008 | 500 | 1,953,625 | - | - | Common stock | |
| Dr. Juliet Singh,PhD | Director, CEO, Director and President, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 26 Sep 2008 | 500 | 1,954,125 | - | - | Common stock | |
| Anthony S. Thornley | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 23 Sep 2008 | 3,000 | 57,900 | - | - | Common stock | |
| Anthony S. Thornley | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 23 Sep 2008 | 3,000 | 60,900 | - | - | Common stock | |
| Anthony S. Thornley | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 10 Sep 2008 | 500 | 54,900 | - | - | Common Stock | |
| Anthony S. Thornley | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 27 Jun 2008 | 4,200 | 54,200 | - | - | Common stock | |
| Dr. Juliet Singh,PhD | Director, CEO, Director and President, Ten Percent Owner | 24 Apr 2008 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | ||
| John T. Lomoro | Chief Financial Officer | 24 Apr 2008 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) |